...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center
【24h】

Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center

机译:早期宫颈癌的II类与III类根治性子宫切除术:在三级中心的观察性研究

获取原文
获取原文并翻译 | 示例

摘要

Aims The purpose of this observational study was to evaluate disease free survival (DFS), overall survival (OS), and local recurrence rate (LRR) in patients submitted to Class II RH compared with Class III RH in early FIGO stage cervical cancer (ECC). Materials and methods We investigated 127 patients with CC admitted to the National Cancer Institute of Milan from June 2001 to October 2011 treated with Class II RH, and compared them with 202 patients operated with Class III RH between March 1980 and March 2001. A total of 329 patients were collected. Results Median follow-up time was 91 months (IQ range:58-196). Five-year OS and DFS estimates were 89.5% (95%CI: 86.0-93.2%) and 85.6% (95%CI: 81.6-89.7%), respectively. Estimates of effect of surgical treatment (Class III RH versus Class II RH) on OS showed a HR of death = 3.38 (95%CI: 1.18-9.63, P = 0.0228), at univariable Cox analysis, and a HR = 3.08 (95%CI: 0.96-9.93; P = 0.0595) at multivariable analysis. For DFS, a HR of relapse = 2.51 (95%CI 1.10-5.72; P = 0.0290) comparing Class III vs Class II was found at multivariable analysis. Overall recurrence rate was 12.8%, whilst it was 16.3% for Class III and 7.1% for Class II respectively. Conclusions The present data suggest that the outcomes of Class II RH are comparable in terms of LRR and OS to those of Class III RH, according to literature data. The opportunity of extending the indication to all women with ECC needs further investigations. Clearer data are warranted by prospective controlled studies.
机译:目的这项观察性研究的目的是评估在FIGO早期宫颈癌(ECC)中接受II类RH和III类RH的患者的无病生存期(DFS),总生存期(OS)和局部复发率(LRR)。 )。材料和方法我们调查了2001年6月至2011年10月收治于米兰国立癌症研究所的127例接受II类RH治疗的CC患者,并与1980年3月至2001年3月之间202例接受III类RH手术的患者进行了比较。收集了329位患者。结果中位随访时间为91个月(IQ范围:58-196)。五年OS和DFS估计分别为89.5%(95%CI:86.0-93.2%)和85.6%(95%CI:81.6-89.7%)。在单变量Cox分析中,手术治疗(III类RH和II类RH)对OS的影响评估显示死亡HR = 3.38(95%CI:1.18-9.63,P = 0.0228),HR = 3.08(95)在多变量分析中,%CI:0.96-9.93; P = 0.0595)。对于DFS,在多变量分析中发现将III类和II类进行比较时,HR复发= 2.51(95%CI 1.10-5.72; P = 0.0290)。总体复发率为12.8%,三级为16.3%,二级为7.1%。结论根据文献数据,目前的数据表明II类RH的结果在LRR和OS方面与III类RH相当。将适应症扩大到所有患有ECC的女性的机会还需要进一步调查。前瞻性对照研究需要更清晰的数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号